Drug Sponsors

Amgen completes Onyx merger

Wednesday, October 2, 2013 01:01 PM

Amgen has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Onyx Pharmaceuticals for $125 per share in cash. As announced Aug. 25, the purchase price is $9.7 billion net of estimated Onyx cash.

More... »

Merck to cut another 8,500 jobs, sharpen pipeline, shutter facilities

Wednesday, October 2, 2013 12:37 PM

In a move to create greater efficiencies, Merck announced the elimination of another 8,500 positions, in addition to previously reported reductions of 7,500 jobs, with a goal of paring annual operating expenses by approximately $2.5 billion by the end of 2015.

More... »

Lundbeck simplifies and restructures, 200 jobs to be cut

Monday, September 30, 2013 03:40 PM

Lundbeck, a global pharmaceutical company specialized in brain diseases, has simplified its commercial structure, increased alignment across countries and improved competencies and investments in market access as a result of its Fit-for-the-Future program.

More... »

GlaxoSmithKline sells brands, plant to Aspen Group

Monday, September 30, 2013 02:50 PM

GlaxoSmithKline has reached agreement to sell its thrombosis brands, Arixtra and Fraxiparine, and the Notre-Dame de Bondeville (NDB) manufacturing site to the Aspen Group, a South African pharmaceuticals company, for $1.13 billion in cash, of which $161.9 million relates to inventory. 

More... »

Ipsen to relocate R&D activities to Cambridge, Mass.

Friday, September 27, 2013 10:28 AM

Ipsen plans to relocate its U.S. R&D operations to Cambridge, Mass., in 2014. This site will be key for innovation in targeted therapies across Ipsen's specialty areas as well as a center of excellence for peptides. The move also brings Ipsen closer to several key partners based in the Cambridge area, including prominent hospital centers, medical schools, biotech companies and universities, thereby further promoting and facilitating partnerships and open innovation.

More... »

Servier makes offer for all shares of Egis Pharmaceuticals

Wednesday, September 25, 2013 12:31 PM

Servier Group has announced a voluntary public offer (to be made by its wholly-owned subsidiary Arts et Techniques du Progrès) to purchase all outstanding shares in its majority-owned subsidiary Egis Pharmaceuticals for $126 per share in cash.

More... »

Sysmex acquires Inostics

Wednesday, September 25, 2013 12:29 PM

Privately-held biotech company Indivumed, based in Hamburg, Germany, has announced that Inostics and its Baltimore-based subsidiary have been sold to Sysmex, a developer and manufacturer of instruments, reagents and software needed for in-vitro diagnostics, headquartered in Japan.

More... »

PRA, RPS merger completed

Wednesday, September 25, 2013 12:23 PM

CRO PRA International has completed its merger with ReSearch Pharmaceutical Services (RPS) and the closing of the acquisition by Kohlberg Kravis Roberts.  

More... »

GSK inks agreement with BARDA to supply anthrax treatment

Friday, September 20, 2013 11:32 AM

GlaxoSmithKline has signed a new four-year contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS), for the provision of its inhalation anthrax treatment, raxibacumab. The U.S. government is purchasing the medicine as a counter measure against a potential bioterrorist attack.

More... »

Medtronic opens Ireland Innovation Center

Wednesday, September 18, 2013 12:44 PM

Medtronic, a Minneaplis, Minn.-based medical technology provider, has opened a new Customer Innovation Center (CIC) in Galway, Ireland, providing state-of-the-art facilities for physicians and Medtronic engineers to develop new therapies that will improve clinical outcomes, provide economic value and increase access to quality healthcare for patients around the world.

More... »